Article

Staged IOL implantation = happy patients

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient.

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient, according to Richard Lindstrom from Minnesota, USA.

Dr Lindstrom conducted a case series in which 23 patients received a dual diffractive IOL combination (ReStor/ReStor; Alcon) and 29 patients were implanted with a diffractive/refractive IOL combination (ReStor/ReZoom; AMO), using the process of staged implantation.

It was discovered that patient satisfaction with distance vision improved from 74% with the dual diffractive IOLs to 96% with the diffractive/refractive combination. Satisfaction with near vision improved from 83% to 96% and willingness to recommend the procedure to others improved from 64% to 96%. Furthermore, subjects with the diffractive/refractive combination reported spectacle independence 94% of the time, compared with just 65% of the time for the subjects with the dual diffractive IOLs.

Dr Lindstrom believes that the staged process can provide the best possible visual outcomes and that combining two different types of refractive IOLs leads to high levels of spectacle independence and patient satisfaction.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.